ABT Abbott Laboratories - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
ABT Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Devices
Current Price
Live
$107.42
Analyst Target
$136.67
+27.2%
Upside
52W High
$141.23
52W Low
$105.78
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$186.96B
P/E
29.19
ROE
13.2%
Profit margin
14.7%
Debt/Equity
0.25
Dividend yield
2.32%
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
Abbott Laboratories has a weak Piotroski F-Score of 4/9, indicating marginal financial health, and lacks an Altman Z-Score for distress risk assessment. While profitability metrics like gross margin and ROE are solid, earnings growth has collapsed YoY (-80.80%), offsetting strong historical earnings surprises. The stock trades at a significant premium to the Graham Number ($49.26) and intrinsic value ($25.76), though forward P/E of 17.24 suggests improvement. Analysts recommend a buy, but insider selling and weak technicals temper near-term optimism.
Key Strengths
Strong gross margin of 56.42% indicates pricing power and efficient production
Low debt/equity ratio of 0.25 reflects conservative capital structure
Consistent earnings beat history: 3 out of last 4 quarters exceeded estimates
Attractive dividend yield of 2.32% with a sustainable payout ratio of 63.44%
Forward P/E of 17.24 is below current P/E of 29.19, pricing in recovery
Key Risks
Piotroski F-Score of 4/9 signals weak financial stability and operational momentum
YoY earnings growth down sharply by 80.80%, raising concerns about near-term profitability
Insider selling activity: $0.95M in sales over last 6 months with no buys
Stock trades at a steep premium to defensive fair value (Graham Number: $49.26 vs price: $107.42)
Technical trend score of 0/100 indicates strong bearish momentum
AI Fair Value Estimate
Based on comprehensive analysis
$49.26
-54.1% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
50
Moderate
35
40
65
42
70
AI Verdict
Neutral with upside potential if earnings recover
Key drivers: Forward P/E improvement, High gross margin, Dividend stability, Weak earnings growth, Bearish insider activity
Confidence
75%
Value
35/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 17.24 is reasonable for healthcare sector
Watchpoints
- Current P/E of 29.19 is high
- Price/Sales of 4.22 above peer average
- Trades at over 2x Graham Number
Future
40/100
Ref Growth rates
Positives
- Forward P/E implies earnings recovery expectations
- Revenue growth stable at 4.40% YoY
Watchpoints
- Earnings growth YoY down 80.80%
- Q/Q earnings also down 80.80%
- PEG Ratio unavailable, limiting growth-adjusted valuation
Past
65/100
Ref Historical trends
Positives
- Long history of beating earnings estimates (22 of 25 quarters positive surprises)
- Average surprise of 0.22% over last 4 quarters, with past spikes over 20%
- 5-year price return of +2.6% despite recent underperformance
Watchpoints
- 1-year return down 11.2%, underperforming sector peers
- 6-month and 1-month returns deeply negative
Health
42/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity of 0.25 is very low, indicating strong balance sheet
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial health
- Missing key ratios: Current Ratio, Quick Ratio, ROA, ROIC
- No Altman Z-Score available for distress risk
Dividend
70/100
Ref Yield, Payout
Positives
- Dividend yield of 2.32% is above S&P 500 average
- Payout ratio of 63.44% is sustainable for mature firm
- Dividend Strength score of 50/100 indicates moderate reliability
Watchpoints
- No 5-year average yield data to assess consistency
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$107.42
Analyst Target
$136.67
Upside/Downside
+27.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ABT and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ABT
Abbott Laboratories
Primary
|
+2.6% | +1.2% | -11.2% | -14.3% | -13.5% | -11.8% |
|
ISRG
Intuitive Surgical, Inc.
Peer
|
+106.2% | +104.4% | -8.4% | +3.2% | -3.9% | -8.7% |
|
DHR
Danaher Corporation
Peer
|
+15.2% | -1.7% | -1.8% | +24.6% | +6.2% | -1.0% |
|
AMGN
Amgen Inc.
Peer
|
+89.3% | +73.4% | +33.3% | +35.4% | +12.5% | +12.4% |
|
GILD
Gilead Sciences, Inc.
Peer
|
+125.7% | +62.5% | +40.1% | +17.0% | +2.9% | +3.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
29.19
Forward P/E
17.24
PEG Ratio
N/A
P/B Ratio
3.67
P/S Ratio
4.22
EV/Revenue
N/A
EV/EBITDA
N/A
Market Cap
$186.96B
Profitability
Profit margins and return metrics
Profit Margin
14.72%
Operating Margin
19.64%
Gross Margin
56.42%
ROE
13.16%
ROA
N/A
Growth
Revenue and earnings growth rates
Revenue Growth
+4.4%
Earnings Growth
-80.8%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-80.8%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.25
Low debt
Current Ratio
N/A
Quick Ratio
N/A
Cash/Share
$N/A
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-15
$N/A
2026-01-22
$1.5
+0.3% surprise
2025-10-15
$1.3
+0.1% surprise
2025-07-17
$1.26
+0.3% surprise
Healthcare Sector Comparison
Comparing ABT against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
P/E Ratio
29.19
This Stock
vs
197.69
Sector Avg
-85.2%
(Discount)
Return on Equity (ROE)
13.16%
This Stock
vs
-56.84%
Sector Avg
-123.1%
(Below Avg)
Profit Margin
14.72%
This Stock
vs
-20.8%
Sector Avg
-170.8%
(Weaker)
Debt to Equity
0.25
This Stock
vs
2.68
Sector Avg
-90.6%
(Less Debt)
Revenue Growth
4.4%
This Stock
vs
61.93%
Sector Avg
-92.9%
(Slower)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ABT
Abbott Laboratories
|
NEUTRAL | $186.96B | 29.19 | 13.2% | 14.7% | $107.42 | |
|
ISRG
Intuitive Surgical, Inc.
|
NEUTRAL | $191.78B | 70.58 | 16.9% | 28.6% | $535.0 | |
|
DHR
Danaher Corporation
|
NEUTRAL | $168.98B | 48.46 | 6.8% | 14.4% | $235.99 | |
|
AMGN
Amgen Inc.
|
NEUTRAL | $207.15B | 27.03 | 106.1% | 21.0% | $384.32 | |
|
GILD
Gilead Sciences, Inc.
|
NEUTRAL | $154.99B | 19.34 | 40.7% | 27.9% | $124.91 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-11 | SALVADORI DANIEL GESUA SIVE | Officer | Gift | 1,536 | $189,358 |
| 2025-11-25 | SHROFF ERIC | Officer | Sale | 1,586 | $203,043 |
| 2025-08-08 | BOUDREAU PHILIP P | Chief Financial Officer | Sale | 5,550 | $746,758 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
25 analysts
Citigroup
2026-01-23
Buy
Buy
Bernstein
2026-01-23
Outperform
Outperform
RBC Capital
2026-01-23
Outperform
Outperform
Oppenheimer
2026-01-23
Outperform
Outperform
Evercore ISI Group
2026-01-23
Outperform
Outperform
Piper Sandler
2026-01-23
Overweight
Overweight
BTIG
2026-01-23
Buy
Buy
Bernstein
2026-01-09
Outperform
Outperform
Barclays
2026-01-05
Overweight
Overweight
BTIG
2025-11-20
Buy
Buy
Past News Coverage
Recent headlines mentioning ABT from our newsroom.
Newest → oldest
No matching news yet.